INBX vs. AMAM, ADAP, FDMT, ADMA, TWST, SANA, AUTL, RLAY, CRGX, and SRRK
Should you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include Ambrx Biopharma (AMAM), Adaptimmune Therapeutics (ADAP), 4D Molecular Therapeutics (FDMT), ADMA Biologics (ADMA), Twist Bioscience (TWST), Sana Biotechnology (SANA), Autolus Therapeutics (AUTL), Relay Therapeutics (RLAY), CARGO Therapeutics (CRGX), and Scholar Rock (SRRK). These companies are all part of the "biological products, except diagnostic" industry.
Ambrx Biopharma (NYSE:AMAM) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking.
Ambrx Biopharma has higher revenue and earnings than Inhibrx.
In the previous week, Inhibrx had 5 more articles in the media than Ambrx Biopharma. MarketBeat recorded 5 mentions for Inhibrx and 0 mentions for Ambrx Biopharma. Inhibrx's average media sentiment score of 1.34 beat Ambrx Biopharma's score of 0.78 indicating that Ambrx Biopharma is being referred to more favorably in the media.
Ambrx Biopharma has a beta of -1.92, meaning that its share price is 292% less volatile than the S&P 500. Comparatively, Inhibrx has a beta of 2.94, meaning that its share price is 194% more volatile than the S&P 500.
Ambrx Biopharma has a net margin of 0.00% compared to Ambrx Biopharma's net margin of -13,408.95%. Inhibrx's return on equity of 0.00% beat Ambrx Biopharma's return on equity.
77.3% of Ambrx Biopharma shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx shares are owned by institutional investors. 0.6% of Ambrx Biopharma shares are owned by company insiders. Comparatively, 25.8% of Inhibrx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Ambrx Biopharma currently has a consensus price target of $24.13, indicating a potential downside of 13.84%. Inhibrx has a consensus price target of $27.00, indicating a potential downside of 22.72%. Given Inhibrx's stronger consensus rating and higher probable upside, research analysts plainly believe Ambrx Biopharma is more favorable than Inhibrx.
Inhibrx received 4 more outperform votes than Ambrx Biopharma when rated by MarketBeat users. Likewise, 60.78% of users gave Inhibrx an outperform vote while only 60.00% of users gave Ambrx Biopharma an outperform vote.
Summary
Ambrx Biopharma beats Inhibrx on 9 of the 16 factors compared between the two stocks.
Get Inhibrx News Delivered to You Automatically
Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools